Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD…
SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the company has regained full rights to CB 2782-PEG, a…